Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

A leak of Phase 3 data for Moderna and Mercks personalized melanoma vaccine triggered a sharp selloff. Although the combination showed benefit over Keytruda alone, traders debate whether the results fell short of expectations after a steep run-up or whether the market overreacted to positive data.

Alphabet shares are under pressure ahead of earnings, with traders focused on whether AI and data-center spending will translate into returns and how management will address capital expenditure and cash-flow concerns. Some see the pullback as a buying opportunity given the companys search, cloud, and AI businesses, while others expect further weakness amid broader tech selling and a deteriorating chart.

Metas post-earnings selloff is centered on concerns that heavier AI infrastructure spending and negative free cash flow could pressure returns, with the new nonvoting share structure adding to worries about potential dilution. Traders are split between viewing the decline as a buying opportunity after strong business results and fearing that AI investment costs and financing needs outweigh the growth outlook.

A sharp pullback from recent highs is driving attention, with traders attributing the weakness to broader market and aerospace-sector pressure, higher fuel costs, and possible institutional selling; these explanations remain speculative. The community is split between investors viewing the decline and ongoing buybacks as an opportunity to add, and bearish traders warning that selling may continue despite confidence in Rolls-Royces longer-term business outlook.

AbbVies Phase 3 hidradenitis suppurativa results are driving discussion: although its drug met the trials primary endpoint, traders view its modest benefit over placebo as potentially easing competitive pressure on MoonLakes sonelokimab. Some also point to the upcoming FDA decision on whether to accept MoonLakes BLA and grant priority review, while the competitive implications remain uncertain.

Nokias quarterly results beat expectations and AI/cloud demand surged, but shares sold off sharply as traders focused on weaker cash-flow guidance, higher restructuring costs, and managements warning that supply constraints are raising costs. The reaction is split between buyers calling the drop an overreaction to the growth story and bears concerned about cash generation and costs.

Nebiuss new Citi financing facility has become a focal point as its shares fall amid a broader selloff in AI infrastructure and neocloud stocks. Bulls view the funding as evidence the company can finance its data-center and GPU expansion, while skeptics worry that more borrowing adds risk as investors reassess the sectors capital needs.

Concerns about Energy Fuels planned VAC acquisition are driving attention after General Motors moved to end a major supply agreement with VACs U.S. subsidiary; the merger agreement was amended to address the dispute, possible debt repayment, and purchase-price adjustments. Traders are split between viewing those provisions as protection for shareholders and worrying that the contract dispute, acquisition costs, and potential dilution add to pressure on the shares, while some remain bullish on the longer-term rare-earth strategy.

CVSs rebound and technical strength are drawing attention ahead of its upcoming earnings report, with traders watching whether the shares can extend their move or stall near resistance. Sentiment is split between bullish call buyers anticipating further gains and traders warning that selling pressure could return.

Crude prices are drawing attention amid fears that escalating Iran, Hormuz and Houthi-related tensions could disrupt oil shipments and supply. Bulls see a geopolitical risk premium, while bears argue that supply flows may be recovering and that unconfirmed peace-deal headlines could quickly unwind the rally.